Patent: 8,007,794
✉ Email this page to a colleague
Summary for Patent: 8,007,794
Title: | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
Abstract: | The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. |
Inventor(s): | Zeller; Joerg (Ann Arbor, MI), Poulsen; Kristian T. (San Francisco, CA), Abdiche; Yasmina Noubia (Mountain View, CA), Pons; Jaume (San Bruno, CA), Collier; Sierra Leigh Jones (Menlo Park, CA), Rosenthal; Arnon (Woodside, CA) |
Assignee: | Rinat Neuroscience Corporation (South San Francisco, CA) |
Application Number: | 12/093,638 |
Patent Claims: | see list of patent claims |
Details for Patent 8,007,794
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | September 14, 2018 | ⤷ Sign Up | 2025-11-14 |
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | January 27, 2020 | ⤷ Sign Up | 2025-11-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,007,794
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2006313434 | ⤷ Sign Up |
Brazil | PI0618705 | ⤷ Sign Up |
Canada | 2626120 | ⤷ Sign Up |
China | 101309704 | ⤷ Sign Up |
China | 103421114 | ⤷ Sign Up |
Costa Rica | 9975 | ⤷ Sign Up |
Cuba | 20080088 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |